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Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells represent a promising effector cell type for adoptive cancer
immunotherapy. Both, genetically modified donor-derived NK cells as well as continuously expanding NK-92 cells are currently under
clinical development. To enhance their therapeutic utility for the treatment of pre-B-cell acute lymphoblastic leukemia (B-ALL), we
engineered NK-92 cells by lentiviral gene transfer to express a FMS-like tyrosine kinase 3 (FLT3)-specific CAR that contains a composite
CD28-CD3ζ signaling domain. FLT3 has primarily been described as a therapeutic target for acutemyeloid leukemia, but
overexpression of FLT3 has also been reported in B-ALL. Exposure of FLT3-positive targets to CAR NK-92 cells resulted in conjugate
formation between NK and leukemia cells, NK-cell degranulation and selective cytotoxicity toward established B-ALL cell lines and
primary blasts that were resistant to parental NK-92. In a SEMB-ALL xenograft model in NOD-SCID IL2R γnull mice, treatment with CAR
NK-92 but not parental NK-92 cells markedly inhibited disease progression, demonstrating high antileukemic activity in vivo. As FLT3
is known to be also expressed on precursor cells, we assessed the feasibility of incorporating an inducible caspase-9 (iCasp9) suicide
switch to enhance safety of our approach. Upon addition of the chemical dimerizer AP20187 to NK-92 cells coexpressing the
FLT3-specific CAR and iCasp9, rapid iCasp9 activation was observed, precluding further CAR-mediated cytotoxicity. Our data
demonstrate that B-ALL can be effectively targeted by FLT3-specific CAR NK cells whichmay complement CD19-directed
immunotherapies, particularly in cases of inherent or acquired resistance to the latter.
Introduction
Pre-B-cell acute lymphoblastic leukemia (B-ALL) typically affects
children but can also be found in adolescents and adults.1 While
long-term survival rates for pediatric B-ALL patients approach
90%,2 relapsed and chemotherapy-refractory disease still remains
a significant cause of cancer-associated mortality. Even if treated
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with pediatric-based ALL regimens, 5-year overall survival for
adult patients does not exceed 60%.3 With the introduction
of CD19-targeted immunotherapies such as the bispecific
CD19xCD3 antibody blinatumomab and CD19-specific chime-
ric antigen receptor (CAR)-engineered T cells, promising treat-
ment alternatives are now available which have demonstrated
remarkable clinical efficacy against B-ALL in pediatric and adult
patients.4–11 Nevertheless, therapy-induced selection of leukemia
cells that show altered CD19 expression or have lost the antigen is
increasingly being recognized as a reason for treatment failure and
relapse.10,12,13 This has spurred the development of CAR T cells
that recognize alternative B-ALL antigens such as CD22.14 Simi-
larly, FMS-like tyrosine kinase 3 (FLT3; CD135) may serve as a
therapeutic target for B-ALL. Activating mutations of FLT3 repre-
sent the most common genetic aberration in acute myeloid leuke-
mia (AML),15 but overexpression of wild-type FLT3 and FLT3
mutations have also frequently been found in B-ALL.16,17
Here we employed genetically modified natural killer (NK) cells
for specific targeting of FLT3-positive B-ALL. NK cells are cytotoxic
lymphocytes of the innate immune system that can get activated
rapidly upon encounter of virally infected, stressed or neoplastic
cells, and play an important role in cancer immunosurveill-
ance.18–20 Unlike T cells, allogeneic NK cells do not carry a high risk
of inducing graft-vs.-host disease, allowing to base clinical protocols
on donor-derived primary NK cells or the clinically applicable NK
cell line NK-92.21,22 Both, primary NK cells and NK-92 engineered
to express CD19-targeted CARs have shown antileukemic activity
in preclinical models of B-ALL,23–27 and early phase clinical trials
with CD19-targeted NK cells for the treatment of B-ALL and other
malignancies of B-cell origin are ongoing (NCT01974479,
NCT03056339; clinicaltrials.gov). To investigate the activity of
FLT3-targeted CAR NK cells against B-ALL, we transduced NK-92
cells with a lentiviral vector encoding a codon-optimized CAR
encompassing an FLT3-specific single chain variable fragment
(scFv) derived from monoclonal antibody 4G8,28 fused to a com-
posite CD28-CD3ζ signaling domain.27,29 We analyzed in vitro
activity of the resulting NK-92/4G8.28.z cells against established
leukemia cell lines and primary B-ALL blasts, and dependence of
cell killing on expression of FLT3 and CAR activation. Antileuke-
mic effects of the CAR NK cells in vivo were investigated in a
human B-ALL xenograft model in NOD-SCID IL2R γnull (NSG)
mice. To tightly control viability and cytotoxicity of the CAR NK
cells, we evaluated co-expression of the FLT3-specific CAR together
with inducible caspase-9 (iCasp9) as a safety switch.
Materials and Methods
Cells and culture conditions
HL-60 acute promyelocytic leukemia cells, and NALM-16 and SEM
B-cell precursor ALL cells were propagated in RPMI 1640 medium
(Lonza, Cologne, Germany). HEK 293T cells were grown inDMEM
(Lonza). Media were supplemented with 10% heat-inactivated FBS,
2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin
(Life Technologies, Darmstadt, Germany). Primary B-ALL blasts
were cultured in Iscove’s modified Dulbecco’s medium (Lonza)
supplemented with 1 μg/ml bovine insulin (Sigma-Aldrich,
Taufkirchen, Germany), 50 μM β-mercaptoethanol, 200 μg/ml
Fe3+-saturated human apo-transferrin (Invitrogen, Karlsruhe,
Germany), 0.6% human serum albumin (Sanquin, Amsterdam,
The Netherlands), 2.0 mM L-glutamine and 20 μg/ml choles-
terol.30 NK-92 cells (kindly provided by NantKwest, Inc., Culver
City, CA) were cultured in X-VIVO 10 (Lonza) containing 5%
heat-inactivated human plasma (German Red Cross BloodDona-
tion Service Baden-Württemberg - Hessen) and 100 IU/ml IL-2
(Proleukin; Novartis Pharma, Nürnberg, Germany).
Generation of CAR-expressing NK-92 cells
CAR 4G8.28.z consists of an immunoglobulin heavy chain signal
peptide, a scFv fragment of FLT3-specific antibody 4G8,28 a Myc-
tag and a modified CD8α hinge region, followed by transmem-
brane and intracellular domains of CD28 and the intracellular
domain of CD3ζ. A codon-optimized CAR sequence was synthe-
sized (GeneArt, Invitrogen) and inserted into lentiviral transfer
plasmid pHR’SIN-cPPT-SIEW (pSIEW) upstream of IRES and
EGFP sequences,31 yielding the vector pS-4G8.28.z-IEW. As a con-
trol, the CAR signaling domains were removed from the construct
by digestion with NaeI and religation, with the resulting pS-4G8.
TM-IEW vector containing a premature stop codon after the trans-
membrane domain of CD28 (CAR 4G8.TM). The integrity of all
constructs was verified by restriction analysis andDNA sequencing.
VSV-G pseudotyped vector particles were produced using HEK
293T cells and NK-92 cells were transduced as described.27 Trans-
duction efficiencies were 8% for pS-4G8.28.z-IEW (MOI of 24) and
18% for pS-4G8.TM-IEW (MOI of 42). EGFP-expressing NK-92
cells were enriched by flow cytometric cell sorting with a FACSAria
fluorescence-activated cell sorter (BD Biosciences, Heidelberg,
Germany). CAR surface expression in sorted single cell clones was
confirmed by flow cytometry with AF647-conjugated Myc-tag-
specific antibody (9E10; Santa Cruz Biotechnology, Heidelberg,
Germany) using a FACSCalibur flow cytometer (BD Biosciences).
Data were analyzed with CellQuest Pro software (BDBiosciences).
What’s new?
Therapy-induced selection of antigen-loss variants can result in resistance of pre-B-cell acute lymphoblastic leukemia (B-ALL)
to CD19-directed immunotherapies. To evaluate FLT3 as a target for B-ALL, here the authors engineered NK-92 cells to express
an FLT3-specific chimeric antigen receptor (CAR). The CAR NK cells displayed high and selective cytotoxicity against
established and primary B-ALL cells in vitro and markedly reduced leukemia burden in a human B-ALL xenograft model in vivo.
The findings suggest FLT3-specific CAR NK cells as a promising alternative approach for adoptive immunotherapy of B-ALL.
against mobilized CD34+ hematopoietic stem cells (HSCs) from
healthy donors was analyzed.
In vivo leukemia model
SEM B-ALL cells were transduced with VSV-G pseudotyped
SEW-luc2 lentiviral vector encoding firefly luciferase and EGFP
linked via a 2A peptide,29,36 and EGFP-positive cells were en-
riched by flow cytometric cell sorting. Six- to eight-week-old male
NSG mice were intravenously (i.v.) injected with 1 × 106
SEM/Luc cells. Beginning 7 days after leukemia induction, animals
were treated by i.v. injection of 1 × 107 NK-92/4G8.28.z or paren-
tal NK-92 cells once per week for 4 weeks. Control mice received
PBS. Disease development was monitored by imaging with an
IVIS Lumina II in vivo imaging system (Perkin Elmer, Rodgau,
Germany) 10 min after intraperitoneal injection of 75 mg/kg
of D-luciferin (Promega, Mannheim, Germany). For endpoint
analysis, mice were sacrificed, spleens were removed, weighed and
immediately analyzed by bioluminescence imaging (BLI), or sub-
jected to immunohistochemical analysis as described below. For
in vivo experiments all applicable guidelines for the care and use
of animals were followed. All animal experiments were approved
by the responsible government committee (Regierungspräsidium
Darmstadt, Darmstadt, Germany).
Immunohistochemistry
Spleen tissues of sacrificedmice were fixedwith phosphate-buffered
4% formaldehyde solution (Roth) and paraffin-embedded. Sections
of 3 μm thickness were deparaffinized and hydrated, and then sta-
ined using a standardized staining protocol (Bond Polymer Refine
IHC protocol, IHC-F; Leica Microsystems) with FLT3-specific
(C-20, 1:50; Santa Cruz Biotechnology) or CD19-specific antibody
(HIB19, 1:100; eBioscience, Frankfurt, Germany) and polymeric
HRP-conjugated anti-mouse secondary antibody (DAB Polymer
Refine Detection Kit; Leica Microsystems). Slides were then stained
with hematoxylin and embedded inmountingmedium.
Analysis of iCaspase-9 activation
NK-92/iCasp9_2A_4G8.28.z and NK-92 control cells were incu-
bated in the absence or presence of 10 nM of AP20187 (Ariad
Pharmaceuticals, Cambridge, MA) for 5, 10 or 30 min. Then the
levels of endogenous caspase-9, iCasp9 and their processed forms
were analyzed by SDS-PAGE of whole cell lysates and immuno-
blotting with caspase-9-specific rabbit antibody (Thermo Scientific,
Braunschweig, Germany), followed by HRP-conjugated secondary
antibody (Sigma-Aldrich) and chemiluminescent detection. In
addition, cytotoxicity assays with NK-92/iCasp9_2A_4G8.28.z or
NK-92/4G8.28.z cells and leukemia target cells were performed in
the presence or absence of 10 nM of AP20187.
Statistical analysis
For comparison of individual values, data were analyzed by
two-tailed unpaired Student’s t-test. For multiple comparisons
of in vivo BLI data, two-way ANOVA with Tukey’s multiple
comparisons test was used. p Values <0.05 were considered
For generation of NK-92 cells coexpressing iCasp9 and the 
FLT3-specific CAR, a sequence encoding codon-optimized iCasp9 
was de novo synthesized (GeneArt, Invitrogen),32,33 linked in 
frame to the CAR 4G8.28.z sequence via a Thosea asigna virus 
self-cleaving peptide and inserted into lentiviral transfer plasmid 
pSIEW, yielding the vector pS-iCasp9-2A-4G8.28.z-W. NK-92 
cells were transduced with VSV-G pseudotyped lentiviral particles 
as described above, and CAR-expressing single cell clones were 
obtained by flow cytometric cell sorting with AF647-conjugated 
Myc-tag-specific antibody.
FLT3 expression, degranulation assay and conjugate 
analysis
FLT3 expression on the surface of NK-92 and leukemia target cells 
was analyzed by flow cytometry using PE-coupled FLT3-specific 
antibody (4G8; BD Pharmingen, Heidelberg, Germany). Degran-
ulation of  NK cells  upon exposure  to  SEM  leukemia  cells  at an  E/T  
ratio of 1:1 for 5 hr at 37C was analyzed as described,34 detecting 
surface expression of lysosomal-associated membrane protein 
LAMP-1 (CD107a) using BD FastImmune CD107a APC anti-
body (BD Biosciences) according to the manufacturer’s instruc-
tions. As controls, NK cells were stimulated with 1 μg/ml phorbol 
12-myristate 13-acetate (PMA) and 1 μg/ml ionomycin (Sigma-
Aldrich). Conjugate formation and redistribution of cytotoxic 
granules were assessed by confocal laser scanning microscopy. NK 
cells and target cells were mixed at a 1:1 ratio and kept on poly-L-
lysine-coated cover slips (Life Technologies) for 1 hr at 37C. 
Then the cells were fixed for 10 min with phosphate-buffered 4%
formaldehyde solution and permeabilized for 5 min with 0.1%
Triton X-100 in phosphate-buffered saline (PBS). After washing 
and blocking of unspecific binding sites for 30 min with 10% FBS 
in PBS, the samples were incubated for 1 hr with perforin-specific 
antibody (δG9; Santa Cruz Biotechnology) and Alexa Fluor
594-coupled anti-mouse secondary antibody (Invitrogen) in 
blocking buffer at room temperature. Nuclei were stained 
with DAPI (40,6-diamidino-2-phenylindole) (Life Technologies). 
After washing with PBS, cells were embedded with Mowiol 4-88 
(Roth, Karlsruhe, Germany) and analyzed using a Leica SP5 con-
focal laser scanning microscope (Leica Microsystems, Wetzlar, 
Germany).
Cytotoxicity assays
Cytotoxicity of NK-92 cells toward established leukemia cell 
lines and primary human B-ALL blasts was analyzed in FACS-
based assays as described.35 Target cells were labeled with calcein 
violet AM (CV) (Molecular Probes, Invitrogen) and incubated 
with effector cells at various effector to target (E/T) ratios for 4 
hr at 37C. Then 150 μl of a 1  μg/ml propidium iodide (PI) 
solution were added to each sample before flow cytometric 
analysis in a FACSCanto II flow cytometer (BD Biosciences). 
Dead target cells were identified as CV and PI double positive. 
Spontaneous target cell lysis in the absence of NK cells was 
subtracted to calculate spe-cific cytotoxicity. Data were analyzed 
using FACSDiva software (BD Biosciences). Likewise, activity of 
NK-92/4G8.28.z cells
statistically significant. Prism 8 software (GraphPad Software,
La Jolla, CA) was used for statistical calculations.
Results
Generation of FLT3-specific CAR NK cells
For targeting of NK cells to the FLT3 differentiation antigen, we
generated a codon-optimized CAR (CAR 4G8.28.z) that harbors
an immunoglobulin heavy chain signal peptide and a scFv derived
from FLT3-specific antibody 4G8,28,37 linked to a composite
CD28-CD3ζ signaling domain via a Myc-tag and an optimized
CD8α hinge region (Supporting Information Fig. S1a).29,38 A
corresponding truncated CAR (CAR 4G8.TM) containing the
transmembrane domain of CD28 but lacking an intracellular sig-
naling domain served as a control (Supporting Information
Fig. S1b). The CAR sequences were inserted into the self-
inactivating lentiviral vector pSIEW, where they are encoded under
the control of the spleen focus forming virus promoter and
coexpressed with an EGFPmarker gene (Fig. 1a; Supporting Infor-
mation Figs. S2a and S2b). VSV-G pseudotyped lentiviral vector
particles were produced and used for transduction of human NK-
92 cells. CAR NK cells were enriched by two rounds of flow
cytometric cell sorting resulting in homogeneous EGFP-positive
NK cell populations (Fig. 1b) with similar surface expression of
full-length and truncated CARs by sorted NK-92/4G8.28.z and
NK-92/4G8.TM single cell clones, respectively (Fig. 1c).
Activation of CAR NK cells upon encounter with
FLT3-positive targets
To confirm the relevance of FLT3 as a therapeutic target for B-
ALL, we investigated FLT3 expression on the surface of established
B-ALL cell lines and primary B-ALL blasts by flow cytometric
analysis with an FLT3-specific antibody. Thereby high FLT3
expression was found for the SEM B-ALL cell line, with more
moderate FLT3 expression determined for the NALM-16 B-ALL
cell line and primary B-ALL blasts (Fig. 2a). In contrast, HL-60
acute promyelocytic leukemia cells included for comparison dis-
played no significant FLT3 expression. Likewise, NK-92 cells
themselves were FLT3-negative. To assess activation of CAR NK
cells in response to FLT3-positive targets, we analyzed activation-
induced degranulation of NK-92/4G8.28.z cells upon contact with
SEM leukemia cells. Cells were coincubated at an effector to target
(E/T) ratio of 1:1 for 5 hr, before surface expression of the lyso-
somal associated membrane protein LAMP-1 (CD107a) was mea-
sured by flow cytometry. CD107a levels were markedly increased
on the surface of NK-92/4G8.28.z cells upon encounter of SEM
cells, but no degranulation of parental NK-92 cells was observed
under the same conditions. In contrast, both, NK-92/4G8.28.z
Figure 1. Generation of CAR NK-92 cells. (a) Lentiviral transfer plasmids encoding full-length or truncated FLT3-specific chimeric antigen
receptors under the control of the spleen focus forming virus promoter (SFFV). The CAR sequences are followed by an internal ribosome entry
site (IRES) and enhanced green fluorescent protein (EGFP) cDNA. In pS-4G8.28.z-IEW the CAR consists of an immunoglobulin heavy chain
signal peptide (SP), a FLT3-specific scFv antibody fragment, a Myc-tag (M), a CD8α hinge region (CD8α), transmembrane and intracellular
domains of CD28 and the intracellular domain of CD3ζ (CAR 4G8.28.z), whereas pS-4G8.TM-IEW encodes a truncated CAR without signaling
capabilities that only harbors the transmembrane domain of CD28 (CAR 4G8.TM). (b) Enhanced green fluorescent protein expression of sorted
NK-92/4G8.28.z and NK-92/4G8.TM single cell clones was determined by direct flow cytometry (filled areas). (c) CAR surface expression was
analyzed by flow cytometry with Myc-tag-specific antibody (filled areas). Parental NK-92 cells served as controls (open areas).
NK-92/4G8.28.z readily formed contacts with FLT3-positive SEM
cells, which triggered reorientation of perforin-containing granules
toward the interface with the target cells and release of cytotoxic
effector molecules, indicated by membrane blebbing and forma-
tion of apoptotic bodies by the leukemia cells (Fig. 2c).
Cytotoxicity of NK-92/4G8.28.z against established and
primary B-ALL cells
To assess antileukemic activity of CAR NK cells in a quantita-
tive manner, in vitro cell killing experiments were performed by
Figure 2. Activation of CAR NK cells by FLT3-positive targets. (a) Expression of FLT3 on the surface of NK-92 cells, HL-60 acute promyelocytic
leukemia, SEM and NALM-16B-ALL cell lines and KWprimary B-ALL blasts was determined by flow cytometry with FLT3-specific antibody (filled
areas). Control cells were stained with an irrelevant antibody of the same isotype (open areas). (b) Degranulation of NK-92/4G8.28.z cells was
analyzed by flow cytometry determining CD107a surface expression after 5 hr of coculture with FLT3-expressing SEM leukemia cells at an E/T ratio of
1:1. Parental NK-92 cells were included for comparison. NK cells stimulated with 1 μg/ml phorbol 12-myristate 13-acetate (PMA) and 1 μg/ml
ionomycin (Iono) served as controls. Mean values SEM are shown; n = 3. p Values were calculated by pairwise analysis using two-tailed unpaired
t-test. ***, p < 0.001; ns: not significant (p > 0.05). (c) Conjugate formation between NK-92/4G8.28.z cells and SEM (upper panel) and HL-60 (lower
panel) leukemia cells was investigated by confocalmicroscopy. Leukemia (L) and EGFP-positive CAR NK (N) cells were co-incubated for 1 hr, fixed,
permeabilized and stained for perforin (red) to identify cytotoxic granules. Cell nuclei were labeled with DAPI (blue). Scale bar: 10 μm.
and NK-92 cells responded strongly to unspecific activation by 
PMA and ionomycin (Fig. 2b). To further confirm specific activa-
tion of NK-92/4G8.28.z by FLT3-positive targets, we investigated 
conjugate formation between CAR NK and leukemia cells and 
polarization of cytotoxic granules to the site of contact by confocal 
laser scanning microscopy with mixed cultures of NK-92/4G8.28.z 
and SEM or HL-60 cells. Cells were cultured at an E/T ratio of 
1:1 for 1 hr, and then stained with perforin-specific antibody  
to visualize cytolytic granules. While no stable conjugates were 
found between NK-92/4G8.28.z and FLT3-negative HL-60 cells,
coincubating established leukemia cells and primary B-ALL blasts
with NK-92/4G8.28.z cells at different E/T ratios. NK-92/4G8.TM
and parental NK-92 cells were included as controls. After 4 hr of
coincubation, NK-92/4G8.28.z cells efficiently and selectively killed
FLT3-positive SEM and NALM-16 B-ALL cell lines and primary
B-ALL blasts, with the degree of cytotoxicity correlating with the
level of FLT3 expressed by the targets and the applied E/T ratio
(Fig. 3). CAR signaling was required for enhanced cell killing, indi-
cated by the observed resistance of SEM leukemia cells and primary
B-ALL blasts to NK-92/4G8.TM cells that carry a FLT3-specific but
signaling-deficient CAR, which mirrored the cells’ resistance to
parental NK-92. FLT3-negative HL-60 acute promyelocytic leuke-
mia cells weremoderately sensitive to unmodifiedNK-92 cells, with
NK-92/4G8.28.z andNK-92/4G8.TMcells not displaying enhanced
cell killing. Human HSCs capable of long-term repopulation have
been described to uniformly express FLT3,39 which could make
them a target for FLT3-specific CAR NK cells and result in unde-
sired effects in a human host. To address this question, we tested
cytotoxic activity of NK-92/4G8.28.z cells against mobilized CD34+
HSCs derived from healthy donors. Thereby no cytotoxicity of the
CARNK cells toward HSCs was observed at the tested E/T ratios of
up to 10:1. Similarly, parental NK-92 cells only displayed marginal
background cytotoxicity towardHSCs (Fig. 3, bottom panel).
Antileukemic activity of NK-92/4G8.28.z cells in a B-ALL
xenograft model
Next we evaluated the in vivo activity of FLT3-specific NK-
92/4G8.28.z cells in an aggressive leukemia xenograft model in
NSG mice. Animals were intravenously injected with 1 × 106
luciferase-expressing SEM cells. One week later, the mice were
treated by intravenous injection of 1 × 107 parental NK-92 or
CAR-expressing NK-92/4G8.28.z cells once per week for 4 weeks
(Fig. 4a). Control animals received PBS. Leukemia development
was monitored at frequent intervals by in vivo BLI. Parental NK-92
cells had no significant effect on leukemia development in compari-
son to PBS treatment, resulting inmarked leukemia growth in bone
marrow, joints, lymph nodes, spleen, liver, brain and along the spi-
nal cord (Fig. 4b). In contrast, therapy with NK-92/4G8.28.z cells
was effective and significantly delayed disease development, with
two out of five animals only showing very moderate leukemia bur-
den at Day 35 (Figs. 4b and 4c). This was confirmed by examination
of excised spleens collected that day for endpoint analysis, which
demonstrated significantly higher spleen weights and BLI signals
for mice treated with parental NK-92 or PBS in comparison to ani-
mals treated with NK-92/4G8.28.z (Figs. 5a and 5b). Likewise,
immunohistochemical analysis showed heavy infiltration of the
spleen with FLT3-positive leukemia cells despite treatment with
parental NK-92 cells, while spleen tissue from an NK-92/4G8.28.z-
treated animal displayed only moderate leukemia growth (Fig. 5c).
Similar data were obtained upon staining of spleen sections with
CD19-specific antibody for detection of SEM B-ALL cells,40 dem-
onstrating that reduced FLT3 signals were indeed due to reduced
leukemia growth and not caused by selection of antigen-loss vari-
ants by treatment with NK-92/4G8.28.z.
Control of NK-92/4G8.28.z activity by an inducible safety
switch
At present, unmodified and CAR-engineered NK-92 cells are irra-
diated before clinical application as allogeneic cell therapeutics to
prevent potential uncontrolled expansion of the immortalized
cells in patients.22,41 This results in loss of effector cells and declin-
ing antitumor activity over time,38,42 likely requiring higher cell
doses and repeated treatments to achieve efficacy. To test whether
safety of FLT3-specific CAR NK-92 cells could also be enhanced
Figure 3. Cytotoxicity of CAR NK cells against established and primary
leukemia cells. Cell killing by CAR-engineered NK-92/4G8.28.z cells
(filled triangles) was investigated in FACS-based cytotoxicity assays
after coincubation with established SEM, NALM-16 and HL-60
leukemia cells lines and KW primary B-ALL blasts as targets at
different effector to target ratios (E/T) for 4 hr. Parental NK-92 (open
circles) and NK-92/4G8.TM cells expressing a truncated CAR (open
triangles) were included for comparison. Similar experiments were
performed to investigate activity of NK-92/4G8.28.z and parental NK-
92 cells against sorted CD34+ hematopoietic stem cells from healthy
donors (bottom panel). Mean values  SEM are shown; n = 3.
p Values for differences between treatments at the indicated E/T
ratios were calculated by pairwise analysis using two-tailed unpaired
t-test (shown for NK-92/4G8.28.z vs. NK-92/4G8.TM). ****,
p < 0.0001; ***, p < 0.001; *, p < 0.05; ns: not significant (p > 0.05).
iCasp9, revealed by immunoblot analysis of whole cell lysates with
caspase-9-specific antibody (Fig. 6c). Interestingly, similar to
parental NK-92 cells, NK-92/iCasp9_2A_4G8.28.z also expressed
large amounts of endogenous pro-caspase-9. While unmodified
NK-92 cells remained unaffected, addition of 10 nM of AP20187
to facilitate homodimerization of the FKBP12 F36V domain rap-
idly induced iCasp9 activation, with marked cleavage of both,
iCasp9 and endogenous pro-caspase-9 already observed after
10 min and almost complete processing after 30 min (Fig. 6c). To
test the effect of iCasp9 activation on the functionality of the CAR
NK cells, in vitro cytotoxicity of NK-92/iCasp9_2A_4G8.28.z cells
against FLT3-expressing SEM and NALM-16 leukemia cells in
the absence or presence of AP20187 was investigated. Most likely
due to minor clonal differences, without the homodimerizer
Figure 4. Inhibition of in vivo leukemia growth by FLT3-specific CAR NK-92 cells. (a) NSG mice were intravenously injected with 1 × 106
SEM/Luc leukemia cells. Starting 7 days after tumor cell inoculation, animals were treated by intravenous injection of 1 × 107 parental NK-92
or CAR-expressing NK-92/4G8.28.z cells once per week for 4 weeks. Control mice received PBS. (b) Leukemia development was monitored by
in vivo bioluminescence imaging. Images taken in dorsal view at Days 20, 27 and 35 are shown (exposure time of 60 sec). (c) Kinetics of
leukemia development. Average radiance values of 60 sec exposure time images recorded in dorsal and ventral positions were used for
calculations. Mean values  SEM are shown; n = 6. p Values for differences between treatment groups were calculated using two-way ANOVA
with Tukey’s multiple comparisons test. ****, p < 0.0001; ns: not significant (p > 0.05).
by incorporation of a suitable suicide gene, we generated NK-92 
cells coexpressing CAR 4G8.28.z and iCasp9. This molecule repre-
sents a fusion of modified FK506 binding protein FKBP12 harbor-
ing an F36V mutation, and truncated caspase-9 lacking the 
caspase activation and recruitment domain.33 iCasp9 and CAR 
sequences were combined in a lentiviral transfer plasmid, con-
nected by a 2A Thosea asigna virus self-cleaving peptide (Fig. 6a; 
Supporting Information Fig. S2c). NK-92 cells were transduced 
with VSV-G pseudotyped lentiviral particles, and CAR-expressing 
cells were enriched by repeated flow cytometric cell sorting with 
Myc-tag-specific antibody recognizing the respective peptide epi-
tope included in the extracellular CAR domain (Fig. 6b). The 
sorted CAR-positive NK-92/iCasp9_2A_4G8.28.z single cell clone 
selected for subsequent experiments also expressed high levels 
of
specific cell killing of NK-92/iCasp9_2A_4G8.28.z was slightly
higher than that of NK-92/4G8.28.z cells, but this was statistically
significant only with NALM-16 target cells at an E/T ratio of 1:1
(p < 0.05). In contrast, when AP20187 was added, cytotoxicity of
NK-92/iCasp9_2A_4G8.28.z cells was completely abrogated
(Fig. 6d). As expected, AP20187 did not affect cell killing by NK-
92/4G8.28.z cells which lack iCasp9. The proportion of viable NK-
92/iCasp9_2A_4G8.28.z cells was reduced to around 11% after
6 hr and 2% after 26 hr of exposure to AP20187, further
supporting suitability of iCasp9 as a safety switch for the CAR
NK-92 cells (Supporting Information Fig. S3).
Discussion
In this work, we investigated NK cells engineered to express an
FLT3-specific CAR as a novel approach to target pre-B-ALL in pre-
clinical in vitro and in vivomodels. While FLT3 has primarily been
described as a therapeutic target for AML, overexpression of wild-
type FLT3 and FLT3mutations have also been found in B-ALL.16,17
As effector cells we employed continuously expanding human
NK-92 cells. In several early stage clinical trials, unmodified NK-92
cells and a CD33-specific CAR-engineered variant have been
safely applied as allogeneic off-the-shelf therapeutics to cancer
patients,41,43–46 with clinical development of other CAR-expressing
NK-92 derivatives ongoing (NCT03383978; clinicaltrials.gov).47
Here, NK-92 cells were transduced with a lentiviral vector
encoding an FLT3-specific CAR encompassing a scFv fragment of
monoclonal antibody 4G8,28 fused to a CD8α hinge region, the
transmembrane domain of CD28, and CD28 and CD3ζ signaling
domains. CD28 and CD3ζ are both endogenously expressed in NK-
92 cells, allowing CD28-CD3ζ CARs to readily link to the respective
signaling pathways.27,35,38,47 Indeed, contact with FLT3-positive
leukemia cells triggered specific activation of CAR-expressing
NK-92/4G8.28.z cells as evidenced by NK-cell degranulation and
reorientation of perforin-containing cytolytic granules to the immu-
nological synapse, which was not observed with untargeted NK-92
cells or FLT3-negative targets, respectively. In in vitro cell killing
assays, FLT3-specific NK-92/4G8.28.z cells efficiently lysed at low
E/T ratios FLT3-positive B-ALL cell lines and primary B-ALL blasts
that were largely resistant to parental NK-92 cells, but showed no
increase in cytotoxicity against FLT3-negative targets. Thereby CAR
signaling was indispensable for enhanced cell killing, demonstrated
by the absence of FLT3-dependent cell lysis in the case of NK-
92/4G8.TM cells that carry a signaling-deficient CAR.
SEM B-ALL cells were chosen as a leukemia xenograft model to
evaluate therapeutic activity of NK-92/4G8.28.z cells in vivo.48
These cells carry high levels of activated wild-type FLT3, and are
exceptionally aggressive and proliferative.49 They readily express
the pan-B-cell marker CD19, but have been described as bipheno-
typic, also displaying myeloid antigens and carrying a t(4;11) chro-
mosomal rearrangement.40,50 This is very similar to phenotype and
genotype described for initially CD19-positive B-ALL, recurring
after CD19 CAR-T cell therapy as CD19-negative disease.13 NSG
Figure 5. Endpoint analysis of leukemia-bearing mice after treatment with FLT3-specific CAR NK-92 cells. Animals from the experiment shown
in Figure 4 were sacrificed for endpoint analysis at Day 35. Spleens were extracted from mice treated with NK-92 or NK-92/4G8.28.z cells,
weighed (a), and immediately analyzed by bioluminescence imaging (b). Data points for individual animals and mean values  SEM are
shown; n = 5. p Values for differences between treatment groups were calculated by pairwise analysis using two-tailed unpaired t-test.
*, p < 0.05; ns: not significant (p > 0.05). (c) Sections of spleen tissues from mice treated with NK-92 or NK-92/4G8.28.z cells were stained
with FLT3- and CD19-specific antibodies for detection of leukemia cells. Scale bars: 300 μm.
only very moderate leukemia development until endpoint analy-
sis at Day 35, indicated by significantly lower overall biolumi-
nescence signals and markedly reduced leukemia infestation in
the spleens. In contrast to human CAR T cells, NK-92 cells and
their CAR-engineered variants do not engraft permanently in
immunodeficient mice and do not expand upon encounter of
target cells.47 Hence, in the murine model application of higher
doses of the CAR NK cells, more frequent treatment intervals,
or further extension of the treatment period may be necessary to
achieve even more effective leukemia control.
Figure 6. Inducible caspase-9 as a safety switch for FLT3-specific CAR NK cells. (a) Lentiviral transfer plasmid encoding under the control of
the spleen focus forming virus promoter (SFFV) inducible caspase-9 (iCaspase-9) and FLT3-specific CAR 4G8.28.z as described in the legend
of Figure 1a, separated by a Thosea asigna virus self-cleaving peptide (2A). (b) CAR surface expression by the selected NK-92/
iCasp9_2A_4G8.28.z single cell clone was confirmed by flow cytometry with Myc-tag-specific antibody (filled area). Parental NK-92 cells
served as control (open area). (c) NK-92/iCasp9_2A_4G8.28.z cells were incubated in the presence of 10 nM of the homodimerizer AP20187
for iCasp9 activation. Lysates of cells collected after 5, 10 or 30 min of exposure to AP20187 were subjected to SDS-PAGE and subsequent
immunoblotting with a caspase-9-specific antibody. Lysates of NK-92/iCasp9_2A_4G8.28.z cells kept without dimerizer and NK-92 cells
incubated in the absence or presence of AP20187 served as controls. (d) Cytotoxicity of NK-92/iCasp9_2A_4G8.28.z cells against
FLT3-expressing SEM and NALM-16 leukemia cells was investigated in flow cytometry-based cytotoxicity assays after coincubation of NK cells
and tumor cells at different effector to target ratios (E/T) for 4 hr in the absence (filled circles) or presence of AP20187 (open circles). NK-
92/4G8.28.z cells without suicide gene were included for comparison in the absence (filled triangles) or presence of AP20187 (open
triangles). Mean values  SEM are shown; n = 4. p Values for differences between treatments at the indicated E/T ratios were calculated by
pairwise analysis using two-tailed unpaired t-test (shown for NK-92/iCasp9_2A_4G8.28.z in the absence vs. NK-92/iCasp9_2A_4G8.28.z in
the presence of AP20187). ****, p < 0.0001; ***, p < 0.001.
mice inoculated with luciferase-expressing SEM cells received 
four weekly treatments by intravenous injection of CAR NK 
cells starting 1 week after leukemia induction, and BLI was per-
formed to monitor disease development. Therapy with parental 
NK-92 cells had no effect in comparison to PBS-treated control 
animals, with overt spreading of leukemia to lymphoid tissues, 
liver, brain and spinal cord. Encouragingly, treatment with four 
weekly doses of NK-92/4G8.28.z cells was effective and led to a 
significant reduction of leukemia burden in comparison to the 
controls, with two out of five animals in this group displaying
Prior to infusion into human cancer patients, NK-92 and CAR
NK-92 cells have so far been irradiated with 10 Gy as a safety
measure,41,43–46 which prevents further proliferation. Irradiation has
no short-term effect on CAR-mediated cytotoxicity (Supporting
Information Fig. S4), but eventually results in a gradual loss of effector
cell activity over time.38,42 While this is not relevant in murine
models, where nonirradiated CARNK-92 do not proliferate and due
to their limited life span in the xenogenic host do not display more
enhanced antitumor activity than their irradiated counterparts,38,51 it
would most likely be different in a human patient, providing a more
suitable environment for human NK cell survival and expansion.
Accordingly, replacement of irradiation of NK-92 cells with a suicide
gene-based approach appears warranted to extend in vivo functional-
ity and enhance efficacy for potential clinical application without
compromising on safety. Here we investigated co-expression of the
FLT3-specific CAR 4G8.28.z together with iCasp9 in NK-92 cells.
iCasp9 can be activated rapidly through addition of otherwise inert
chemical inducers of dimerization of its modified FKBP12 domain
such as rimiducid (AP1903) or the AP20187 compound used in our
study,33 and has been employed successfully to control development
of graft-vs.-host disease after infusion of genetically modified donor-
derived T cells in haploidenticalHSC transplant patients.52
Indeed, sorted NK-92/iCasp9_2A_4G8.28.z cells coexpressed
CAR and iCasp9 as evidenced by flow cytometry and immunoblot
analysis of whole cell lysates. While most of iCasp9 and endoge-
nous pro-caspase-9 were found as intact full-length proteins, a
distinct signal corresponding to the p35 iCasp9/caspase-9 cleavage
product was noted in the absence of chemical dimerizer suggesting
some spontaneous iCasp9 cleavage. Nevertheless, the cells contin-
ued to expand, indicating that a limited degree of iCasp9
autoactivation is tolerable for NK-92.When iCasp9 was specifically
activated by addition of AP20187, a large proportion of iCasp9 and
pro-caspase-9 were fully processed already after 10 min, with no
intact iCasp9 and only very little unprocessed pro-caspase-9
remaining after 30 min. iCasp9 activation precluded cell killing by
NK-92/iCasp9_2A_4G8.28.z cells, evidenced by a complete lack of
CAR-mediated cytotoxicity in the presence of AP20187. Also via-
bility of NK-92/iCasp9_2A_4G8.28.z cells was strongly affected by
iCasp9 activation, resulting in a progressive loss of viable cells over
time, with only around 2% remaining after 26 hr of exposure to
the chemical dimerizer (Supporting Information Fig. S3). These
data demonstrate that iCasp9 can indeed be applied as an inducible
safety switch for CAR-engineered NK-92 cells, whichmay not only
bypass the need for γ-irradiation, but also provide a means to con-
trol possible adverse events as currently done in the case of
CD19-CAR engineered NK cells derived from cord blood.24
FLT3 is expressed on normal human HSC and precursor cells,39
raising the possibility of CAR-mediated cytotoxicity against these
cell types. In a previous study parental antibody 4G8 on its own did
not affect colony formation and was not cytotoxic toward
CD34-positive human bone marrow cells.28 Likewise, two prior
studies with T cells carrying CARs based on FLT3-specific scFv anti-
body or FLT3 ligand reported normal human hematopoiesis in
NSG mice transplanted with HSCs after treatment with the
FLT3-specific CAR T cells, and undisturbed colony formation of
cord blood derived HSCs in the presence of CAR T cells, respec-
tively.53,54 In contrast, in another recent report, a marked reduction
in colony formation and HSC viability was observed upon exposure
of HSCs to FLT3-targeted CAR T cells.55 Here we did not observe
CAR-mediated killing of mobilized human CD34-positive HSCs by
NK-92/4G8.28.z cells at the tested E/T ratios. Nevertheless, given the
diverging data with FLT3-specific CAR T cells, FLT3 expression by
HSCs and sensitivity to FLT3-targeted agents may be different for
individual donors or patients. Accordingly, potential negative effects
of NK-92/4G8.28.z cells on normal hematopoiesis cannot be fully
excluded at this point, underscoring the importance of employing a
suitable safetymeasure such as iCasp9 in a clinical setting.
Taken together, our data demonstrate that B-ALL can be effec-
tively targeted by continuously expanding NK cells engineered with
an FLT3-specific CAR. This approach may complement CD19
CAR expressing effector cells, in particular in cases of acquired resis-
tance to the latter due to treatment-induced selection of antigen-loss
variants. We showed that iCasp9 can be readily employed as an
inducible safety switch in FLT3-specific CAR NK-92 cells, where it
may serve a dual function, allowing to bypass γ-irradiation as a
safety measure for clinical application, but also to rapidly inactivate
the effector cells in case of serious adverse reactions.
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